

Borysowski J and Górska A. Compassionate use of unauthorized drugs: Legal regulations and ethical challenges. *Eur J Intern Med.* 2019. [DOI. Opens in a new tab.](#)

Feit NZ ... Hyman DM. Use, safety, and efficacy of single-patient use of the US Food and Drug Administration expanded access program. *JAMA Oncol.* 2019. [DOI. Opens in a new tab.](#)

Florko N. [A year after Trump touted ‘right to try,’ patients still aren’t getting treatment. Opens in a new tab.](#) *STAT News.* January 29, 2019.

Kelman A, Kang A, and Crawford B. Continued access to investigational medicinal products for clinical trial participants—An industry approach. *Cambridge Quarterly of Healthcare Ethics.* 2019. [DOI. Opens in a new tab.](#)

Lanzel AF and Lavery JV. Unintended consequences of the Right to Try Act for palliative care in pediatric oncology. *JAMA Oncol.* 2019. [DOI. Opens in a new tab.](#)

Moerdler S ... Weiser DA. Physician perspectives on compassionate use in pediatric oncology. *Pediatr Blood Cancer.* 2019. [DOI. Opens in a new tab.](#)

Spector-Bagdady K ... Shuman AG. The critical role of medical institutions in expanding access to investigational interventions. *Hastings Cent Rep.* 2019. [DOI. Opens in a new tab.](#)

Fernandez Lynch H, Zettler PJ, and Sarpatwari A. Promoting patient interests in implementing the federal Right to Try Act. *JAMA.* 2018. [DOI. Opens in a new tab.](#)

Joffe S and Fernandez Lynch H. Federal Right-to-Try Legislation—Threatening the FDA’s Public Health Mission. *N Engl J Med.* 2018. [DOI. Opens in a new tab.](#)

Kapczynski A. [Dangerous times: The FDA’s role in information production, past and future. Opens in a new tab.](#) *Minnesota Law Review.* 2018.

London AJ. Social value, clinical equipoise, and research in a public health emergency. *Bioethics.* 2018. [DOI. Opens in a new tab.](#)

Neuhaus CP and Zacharias RL. Compassionate use of gene therapies in pediatrics: An ethical analysis. *Semin Perinatol.* 2018. [DOI. Opens in a new tab.](#)

Thomas K. [Why can’t dying patients get the drugs they want?. Opens in a new tab](#) *The New York Times.* March 23, 2018.

Jarow JP and Moscicki R. Impact of expanded access on FDA regulatory action and product labeling. *Ther Innov Regul Sci.* 2017. [DOI. Opens in a new tab.](#)

Jarow JP ... Moscicki R. Expanded access of investigational drugs: The experience of the Center of Drug Evaluation and Research over a 10-year period. *Ther Innov Regul Sci.* 2016. [DOI. Opens in a new tab.](#)

Piel J. [Informed consent in right-to-try cases. Opens in a new tab.](#) *J Am Acad Psychiatry Law.* 2016;44(3):290–296.

Darow JJ ... Kesselheim AS. Practical, legal, and ethical issues in expanded access to investigational drugs. *N Engl J of Med.* 2015. [DOI. Opens in a new tab.](#)

Dresser R. [The ‘right to try’ investigational drugs: Science and stories in the access debate. Opens in a new tab.](#) *Texas Law Review.* 2015.

Adriance S. [Fighting for the “Right to Try” unapproved drugs: Law as persuasion. Opens in a new tab.](#) *The Yale Law Journal.* December 4, 2014.

Zettler PJ and Greely HT. The strange allure of state “right-to-try” laws. *JAMA Inter Med.* 2014. [DOI. Opens in a new tab.](#)

Jacobson PD and Parmet WE. A new era of unapproved drugs: The case of *Abigail Alliance v Von Eschenbach.* *JAMA.* 2007. [DOI. Opens in a new tab.](#)

Groopman J. [The right to a trial. Opens in a new tab.](#) *The New Yorker.* December 10, 2006.